About Atea Pharmaceuticals
Atea Pharmaceuticals is a company based in Boston (United States) founded in 2014 by Jean Pierre Sommadossi. It operates as a Professional Services. Atea Pharmaceuticals has raised $293.43 million across 6 funding rounds from investors including Bain Capital, RA Capital and Perceptive Advisors. The company has 56 employees. Atea Pharmaceuticals offers products and services including Bemnifosbuvir + Ruzasvir and AT-527. Atea Pharmaceuticals operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Boston, United States
- Employees 56
- Founders Jean Pierre Sommadossi
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website ateapharma.com
- Social LinkedIn X
- Legal Name Atea Pharmaceuticals, Inc.
- Net Profit-$158.35 M (USD)5.96as on Dec 31, 2025
- EBITDA-$180.47 M (USD)6.27as on Dec 31, 2025
- Total Equity Funding$293.43M (USD)
in 6 rounds
- InvestorsBain Capital
& 11 more
- Employee Count56
Products & Services of Atea Pharmaceuticals
Atea Pharmaceuticals offers a comprehensive portfolio of products and services, including Bemnifosbuvir + Ruzasvir and AT-527.
Combination therapy developed for treating Hepatitis C virus.
Therapy developed for treatment of COVID-19 patients.
Funding Insights of Atea Pharmaceuticals
Atea Pharmaceuticals has successfully raised a total of $293.43M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $293.43M
- Total Rounds 6
- First Round $10M
(May 2014)
- Investors Count 12
All 6 funding rounds of Atea Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | – | Post-IPO | – | GSA Capital Partners | – |
| May 2020 | $215M | Series D | – | Bain Capital | |
| Jul 2018 | $27.6M | Series C | – | – | – |
| Sep 2016 | $20.83M | Series A | – | – | – |
| Sep 2014 | $20M | Series A | – | – | – |
| May 2014 | $10M | Series A | – | – | – |
12 investors in total: 12 institutional.
Investors in Atea Pharmaceuticals
Atea Pharmaceuticals has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Bain Capital, RA Capital and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Debt and equity investments are pursued across multiple sectors. | 1984 | baincapital.com | Boston, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Venture capital firm | – | omegafunds.com | Boston, United States | |
Multiple sectors are invested in by Morningside, a VC fund. | – | morningside.com | Newton, United States | |
Private equity and hedge fund investments in healthcare are managed. | – | ally-bridge.com | Hong Kong, China | |
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Quantitative trading firm delivering returns through systematic strategies across asset classes. | 2005 | gsacapital.com | London, United Kingdom | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States |
Investor details for Atea Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Atea Pharmaceuticals
41 people are tracked at Atea Pharmaceuticals (31 in leadership, 6 in board & advisors, 4 in team); the tracked headcount is 56.
| Name | Role | Group |
|---|---|---|
Jean Pierre Sommadossi | Founder & CEO | Leadership |
Jingyang Wang | Executive Director, Analytical Development | Leadership |
Ariyapadi Krishnaraj | Vice President Marketing | Leadership |
Bruce Belanger | Vice President, Biostatistics | Leadership |
Wayne Foster | EVP And Chief Accounting Officer | Leadership |
Arantxa Horga | Executive Vice President | Leadership |
John Vavricka | Chief Commercial Officer | Leadership |
Andrea Corcoran | CFO & EVP, Legal | Leadership |
Adel Moussa | Executive Vice President, Chemistry | Leadership |
Janet Hammond | Chief Development Officer | Leadership |
Keith Pietropaolo | Vp, Clinical Operations And Project Management | Leadership |
Brian Rowe | VP, Business Development | Leadership |
Xiao-Jian Zhou | Executive Vp, Early-stage Development | Leadership |
James MB Evans | VP, CMC Manufacturing | Leadership |
Amy Kasparian | Legal Counsel & Director, Contracts | Leadership |
Jayanthi Wolf | Evp, Head Of Regulatory Affairs And Quality Assurance | Leadership |
Patrick Scoble | Senior Director, Medical Affairs | Leadership |
Robert Nigro | VP Of IT | Leadership |
Sydney Burke | Associate Director, R&d Quality Assurance | Leadership |
Marc van Hulle | Vice President Finance | Leadership |
21 more people are available in the full profile.
Complete people profiles for Atea Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Atea Pharmaceuticals
Atea Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AVIR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Oct 2020
- Listed onNASDAQ: AVIR
- Listed entityAtea Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS04683R1068
- Share price$5.16 (+2.89% on the day) · 2026-10-08
- Market capitalisation$413.5M
- EPS (diluted, trailing year)$-2.09
- Volume (last session)350,918
Financials of Atea Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$158.3M | -$180.5M |
| 2024 | – | -$168.4M | -$192.5M |
| 2023 | – | -$136.0M | -$163.8M |
| 2022 | – | -$115.9M | -$130.4M |
| 2021 | $351.4M | $121.2M | $138.4M |
Detailed financial statements for Atea Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Atea Pharmaceuticals
4 dated milestones of Atea Pharmaceuticals across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Atea Pharmaceuticals is founded.
- Funding First funding round of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Atea Pharmaceuticals
Atea Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| novavax.com | 1987 | Gaithersburg, United States | – | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| molecularpartners.com | 2004 | Zurich, Switzerland | $59.94M | – | Therapeutic solutions for diseases are developed using DARPin technology. |
Detailed competitors of Atea Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Atea Pharmaceuticals
The website of Atea Pharmaceuticals (ateapharma.com) receives about 3.6K visits a month and ranks #3,587,443 among all websites worldwide, #4,621 in Biotechnology and Pharmaceuticals.
- Monthly visits3.6K
▼ 32.3% vs previous month
- Unique visitors2.1K
per month
- Global rank#3,587,443
among all websites
- Category rank#4,621
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit38 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with Atea Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| atea.com | 100% | 76.1K | #517,804 | View details |
Latest news on Atea Pharmaceuticals
Complete news archive for Atea Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Atea Pharmaceuticals
10 companies that operate in the same segment as Atea Pharmaceuticals (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Atea Pharmaceuticals
Atea Pharmaceuticals was founded in 2014.
Atea Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jean Pierre Sommadossi is the current CEO of Atea Pharmaceuticals. They have also founded this company.
Atea Pharmaceuticals is a funded company, having raised a total of $293.43M across 6 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on May 2014.
Atea Pharmaceuticals has 56 employees.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapies for serious viral diseases. The company is primarily engaged in advancing treatments for Hepatitis C virus (HCV) through its regimen of bemnifosbuvir and ruzasvir, which is in a global Phase 3 development program. Additionally, innovative therapies are being developed to address unmet medical needs in the antiviral sector, including collaborations for COVID-19 treatments. A deep understanding of antiviral drug development, medicinal chemistry, and virology is leveraged to create novel product candidates targeting single-stranded RNA viruses.
Atea Pharmaceuticals's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Atea Pharmaceuticals offers Bemnifosbuvir + Ruzasvir and AT-527.
Yes, Atea Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AVIR.
Atea Pharmaceuticals has 12 investors. Key investors include Bain Capital, RA Capital, Perceptive Advisors, GSA Capital Partners, and Rock Springs Capital.
Atea Pharmaceuticals operates through Atea Pharmaceuticals, Inc..